TC Biopharm (TCBP) Stock Price, News & Analysis

Company Overview

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Key Stats

• Today's Range: $0.50 to $0.50
• 50-Day Range: $0.68 to $0.68
• 52-Week Range: $0.50 to $160.00
• Volume: N/A
• Average Volume: 177,918 shs
• Market Capitalization: $205 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TCBP Stock Analysis - Frequently Asked Questions

When did TC Biopharm's stock split?

Shares of TC Biopharm reverse split on the morning of Monday, February 10th 2025.The 1-20 reverse split was announced on Wednesday, February 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did TC Biopharm IPO?

TC Biopharm (TCBP) raised $17 million in an initial public offering on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton acted as the underwriter for the IPO.

What other stocks do shareholders of TC Biopharm own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TC Biopharm investors own include Johnson & Johnson (JNJ), Procter & Gamble (PG), Taiwan Semiconductor Manufacturing (TSM), ExxonMobil (XOM), International Business Machines (IBM), NextEra Energy (NEE) and Union Pacific (UNP).

Company Calendar

• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCBP
• CIK: 1872812
• Web: www.tcbiopharm.com
• Phone: 44-14-1433-7557
• Fax: N/A
• Employees: 80
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 1.12
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $4.76 million
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $519.58 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 410,000
• Free Float: 28,000
• Market Cap: $205 thousand
• Optionable: Not Optionable
• Beta: 0.01